MONTREAL, QUEBEC -- (MARKET WIRE) -- May 01, 2007 -- Alethia Biotherapeutics Inc. and Emerillon Therapeutics Inc, both privately held biotechnology companies, announced today that they have signed a collaborative research agreement to conduct a discovery and functional validation program to identify new drug candidates for the treatment of bone-related diseases such as osteoporosis. Under the terms of the collaboration, Emerillon will provide Alethia with a list of genetic loci that are associated with an osteoporotic phenotype in mice. In return, Alethia will generate bone-specific cDNA libraries to help identify these genes. Furthermore, Alethia will conduct cell-based validation studies to determine the functional relevance of the genes provided by Emerillon.
